Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.64 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.64 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.64 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.64 |
| ▸ | ACE | P12821 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | FAP | Q12884 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14634819 | 1.00 | DPP4 (0.64) | DPP4DPP8DPP9DPP7ACE | |
| Phosphoric Acid SCHEMBL20162034 | 0.95 | DPP4 (0.67) | DPP4DPP8DPP9DPP7ACE | |
| Phosphoric Acid SCHEMBL16227292 | 0.80 | DPP4 (0.72) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL13730075 | 0.79 | DPP4 (0.62) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL15477372 | 0.79 | DPP4 (0.62) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL28557785 | 0.78 | DPP4 (0.57) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL5138244 | 0.78 | DPP4 (0.47) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL7891864 | 0.78 | DPP4 (0.67) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL17783 | 0.78 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL19520418 | 0.78 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011109787-A1 | METHODS OF ADMINISTERING INSULINOTROPIC PEPTIDES | CONJUCHEM, LLC (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011109784-A1 | FORMULATION OF INSULINOTROPIC PEPTIDE CONJUGATES | CONJUCHEM, LLC (US) | 2011-09-09 | — | — | WO | disclosed |
| EP-1951286-A1 | COMBINED USE OF DPP IV INHIBITORS AND GASTRIN COMPOUNDS | Waratah Pharmaceuticals, Inc. (CA) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007041833-A1 | COMBINED USE OF DPP IV INHIBITORS AND GASTRIN COMPOUNDS | WARATAH PHARMACEUTICALS, INC. (CA) | 2007-04-19 | — | — | WO | disclosed |
| EP-1732562-A2 | SUBSTITUTED PYRIDINYL AND PYRIMIDINYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006083491-A2 | SUBSTITUTED PYRIDINYL AND PYRIMIDINYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |